menu

Who May Benefit From Increased Awareness of RSV and Why?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Addressing the Morbidity in RSV: Patients, Treatment Approaches, and Vaccines

Who May Benefit From Increased Awareness of RSV and Why?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including pediatricians, family practice, general practice, internal medicine, pulmonology/critical care, hospital medicine, infectious disease and advanced practice providers (nurse practitioners, physician assistants, nurses, and pharmacists) involved in the prevention of respiratory syncytial virus (RSV).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Increase knowledge of the clinical presentation of RSV across “at risk” patient populations at high risk of severe RSV. 
    • Review historical RSV vaccination/treatment failures, key learnings of researchers toward development of future RSV vaccines and immunoprophylaxis. 
    • Highlight common theories and issues around vaccine hesitancy with best practices to overcome these. 
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Vikram Anand, MD, PhD, faculty for this educational event, has no relevant financial relationships with ineligible companies.    

    Priya Soni, MD, FAAP, faculty for this educational event, has no relevant financial relationships with ineligible companies.    

    Eric Simões MB, BS, DCH, MD, Faculty for this educational event, is a contracted researcher for AstraZeneca, Merck & Co., Pfizer, Roche Pharmaceuticals, and Johnson and Johnson; receives consulting fees from Abbvie Inc, GlaxoSmithKline plc Bill and Melinda Gates Foundation,  Merck & Co., Pfizer Inc, Sanofi Pasteur, Cidara Therapeutics, Adiago Therapeutics, Nuance Pharmaceuticals, Icosavax, Johnson and Johnson, and Sobi Inc.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Vin Kalathiveetil, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.
    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 4/28/2023 through 4/28/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule14 Apr 2024